Unicycive Therapeutics (NASDAQ:UNCY) Lifted to “Strong-Buy” at Brookline Capital Management

Unicycive Therapeutics (NASDAQ:UNCYGet Free Report) was upgraded by stock analysts at Brookline Capital Management to a “strong-buy” rating in a research note issued on Tuesday, Zacks.com reports.

UNCY has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $4.50 target price on shares of Unicycive Therapeutics in a research report on Wednesday. Piper Sandler assumed coverage on shares of Unicycive Therapeutics in a research report on Thursday, April 4th. They set an “overweight” rating and a $9.00 price objective for the company. Finally, Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, May 31st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $5.63.

Read Our Latest Analysis on UNCY

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $0.49 on Tuesday. The business has a 50 day moving average of $0.79 and a 200-day moving average of $1.05. Unicycive Therapeutics has a 1 year low of $0.34 and a 1 year high of $1.82. The company has a market capitalization of $18.27 million, a P/E ratio of -0.41 and a beta of 2.39.

Unicycive Therapeutics (NASDAQ:UNCYGet Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Equities analysts anticipate that Unicycive Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

Several large investors have recently modified their holdings of the stock. Rosalind Advisors Inc. bought a new position in shares of Unicycive Therapeutics in the 1st quarter worth $2,594,000. BVF Inc. IL lifted its holdings in shares of Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after purchasing an additional 1,493,462 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Unicycive Therapeutics in the 1st quarter worth $36,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Read More

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.